
Incyte Corporation
INCYHealthcare|Biotechnology|US
$119.65
+1.64 (+1.39%)
DCF Value
$113.08
Tangible Book / Share
$26.60
Graham Number
$35.21
Cash / Share
$18.97
Financials
Financial Snapshot
Market Cap
$24.39B
Enterprise Value
$21.15B
Revenue (TTM)
$6.01B
Net Income (TTM)
$403.4M
Cash & Investments
$3.85B
Net Cash
$3.82B
Free Cash Flow (TTM)
$684.9M
Operating CF (TTM)
$745.0M
Debt/Equity
0.01
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $808.5M | $1.17B | $1.44B | $2.12B | $1.80B | $2.35B | $3.24B | $3.66B | $2.16B | $3.58B | $3.85B | |
| Operating Cash Flow | $304.8M | -$93.0M | $336.2M | $710.7M | -$124.6M | $749.5M | $969.9M | $496.5M | $335.3M | $1.41B | $745.0M | |
| Free Cash Flow | $184.5M | -$204.0M | $262.7M | $632.6M | -$312.0M | $568.5M | $892.1M | $464.0M | $249.1M | $1.35B | $684.9M | |
| Capital Expenditure | -$120.3M | -$111.0M | -$73.5M | -$78.1M | -$187.4M | -$181.0M | -$77.8M | -$32.5M | -$86.3M | -$58.9M | -$60.1M | |
| Financing Cash Flow | $58.6M | $690.2M | $14.7M | $45.7M | $71.7M | $6.2M | -$794.0K | -$20.0M | -$2.02B | $101.0M | $302.0M |
R&D Spending
R&D (TTM)
$3.44B
R&D Intensity
57.2%
R&D Growth vs Prior
+67.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.54B | $1.88B | $2.16B | $2.67B | $2.99B | $3.39B | $3.70B | $4.24B | $5.14B | $6.01B | |
| R&D Expense | $581.9M | $1.33B | $1.20B | $1.15B | $2.22B | $1.46B | $1.59B | $1.63B | $2.61B | $2.05B | $3.44B | |
| R&D % of Revenue | 52.6% | 86.3% | 63.7% | 53.5% | 83.1% | 48.8% | 46.7% | 44.0% | 61.5% | 39.9% | 57.2% | |
| SG&A | $303.3M | $366.3M | $434.4M | $468.7M | $516.9M | $739.6M | $1.00B | $1.16B | $1.22B | $1.38B | $1.43B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.54B | $1.88B | $2.16B | $2.67B | $2.99B | $3.39B | $3.70B | $4.24B | $5.14B | $6.01B | |
| Cost of Revenue | $58.2M | $79.5M | $94.1M | $114.2M | $131.3M | $151.0M | $207.0M | $255.0M | $312.1M | $372.1M | $439.3M | |
| Gross Profit | $1.05B | $1.46B | $1.79B | $2.04B | $2.54B | $2.84B | $3.19B | $3.44B | $3.93B | $4.77B | $5.57B | |
| R&D | $581.9M | $1.33B | $1.20B | $1.15B | $2.22B | $1.46B | $1.59B | $1.63B | $2.61B | $2.05B | $3.44B | |
| SG&A | $303.3M | $366.3M | $434.4M | $468.7M | $516.9M | $739.6M | $1.00B | $1.16B | $1.22B | $1.38B | $1.43B | |
| Operating Income | $145.0M | -$243.4M | $129.2M | $402.0M | -$263.7M | $585.8M | $591.6M | $655.4M | $101.3M | $1.34B | $697.7M | |
| Interest Expense | $38.7M | $6.9M | $1.5M | $1.9M | $2.2M | $1.9M | $2.7M | $2.6M | $2.3M | $2.4M | $2.3M | |
| Pretax Income | $107.4M | -$312.3M | $115.3M | $486.8M | -$232.2M | $570.4M | $529.1M | $834.2M | $316.6M | $1.66B | $796.2M | |
| Net Income | $104.2M | -$313.1M | $109.5M | $446.9M | -$295.7M | $948.6M | $340.7M | $597.6M | $32.6M | $1.29B | $403.4M | |
| EPS (Diluted) | 0.54 | -1.53 | 0.51 | 2.05 | -1.36 | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 | 1.88 | |
| EBITDA | $204.6M | -$253.2M | $171.9M | $543.2M | -$178.2M | $630.2M | $599.6M | $919.4M | $408.2M | $1.76B | $872.8M | |
| Shares Out. (M) | 194.13 | 204.58 | 215.63 | 217.66 | 218.07 | 222.07 | 223.96 | 225.93 | 210.53 | 200.70 | 203.25 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $652.3M | $899.5M | $1.16B | $1.83B | $1.51B | $2.06B | $2.95B | $3.21B | $1.69B | $3.10B | $3.28B | |
| Short-Term Investments | $156.2M | $270.1M | $274.3M | $284.9M | $288.4M | $290.8M | $287.5M | $442.7M | $470.3M | $482.8M | $578.7M | |
| Total Current Assets | $994.2M | $1.50B | $1.83B | $2.48B | $2.36B | $3.12B | $4.09B | $4.65B | $3.24B | $5.02B | $5.52B | |
| Total Assets | $1.64B | $2.30B | $2.65B | $3.43B | $3.56B | $4.93B | $5.84B | $6.78B | $5.44B | $6.96B | $7.29B | |
| Total Current Liabilities | $273.5M | $375.4M | $425.3M | $513.3M | $631.2M | $854.3M | $1.16B | $1.24B | $1.64B | $1.52B | $1.44B | |
| Long-Term Debt | $651.5M | $16.6M | $17.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $14.5M | $0.00 | |
| Total Liabilities | $1.22B | $672.0M | $719.8M | $828.3M | $949.6M | $1.16B | $1.47B | $1.59B | $2.00B | $1.80B | $1.64B | |
| Stockholders' Equity | $419.5M | $1.63B | $1.93B | $2.60B | $2.61B | $3.77B | $4.37B | $5.19B | $3.45B | $5.17B | $5.64B | |
| Retained Earnings | -$1.67B | -$1.99B | -$1.88B | -$1.43B | -$1.73B | -$777.9M | -$437.2M | $160.4M | -$1.07B | $213.8M | $317.9M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $304.8M | -$93.0M | $336.2M | $710.7M | -$124.6M | $749.5M | $969.9M | $496.5M | $335.3M | $1.41B | $745.0M | |
| Capital Expenditure | -$120.3M | -$111.0M | -$73.5M | -$78.1M | -$187.4M | -$181.0M | -$77.8M | -$32.5M | -$86.3M | -$58.9M | -$60.1M | |
| Free Cash Flow | $184.5M | -$204.0M | $262.7M | $632.6M | -$312.0M | $568.5M | $892.1M | $464.0M | $249.1M | $1.35B | $684.9M | |
| Investing Cash Flow | -$232.5M | -$350.0M | -$86.4M | -$87.5M | -$269.0M | -$207.7M | -$78.5M | -$207.7M | $157.5M | -$102.6M | -$221.8M | |
| Financing Cash Flow | $58.6M | $690.2M | $14.7M | $45.7M | $71.7M | $6.2M | -$794.0K | -$20.0M | -$2.02B | $101.0M | $302.0M | |
| Issuance of Stock | $50.0M | $716.2M | $29.9M | $63.3M | $110.3M | $58.6M | $61.1M | $35.8M | $49.3M | $221.8M | $455.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.00B | -$19.1M | $0.00 | |
| Net Debt Issuance | -$445.0K | $0.00 | $0.00 | -$822.0K | -$836.0K | -$2.4M | -$2.9M | -$3.4M | -$3.8M | -$4.5M | -$4.6M | |
| Stock Based Comp. | $96.2M | $133.1M | $148.2M | $166.6M | $177.9M | $183.0M | $188.4M | $215.9M | $266.1M | $249.3M | $263.3M | |
| Net Change in Cash | $130.4M | $247.2M | $264.5M | $668.7M | -$319.7M | $544.4M | $894.0M | $262.0M | -$1.53B | $1.41B | $822.6M |
Dilution Tracker
Shares Outstanding
204M
5-Year Share Growth
-8.0%
Stock Issuance (TTM)
$455.6M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 194.13 | 204.58 | 215.63 | 217.66 | 218.07 | 222.07 | 223.96 | 225.93 | 210.53 | 200.70 | 203.25 | |
| Change vs Prior % | — | 5.4% | 5.4% | 0.9% | 0.2% | 1.8% | 0.8% | 0.9% | -6.8% | -4.7% | 1.3% | |
| Stock Issuance | $50.0M | $716.2M | $29.9M | $63.3M | $110.3M | $58.6M | $61.1M | $35.8M | $49.3M | $221.8M | $455.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.00B | -$19.1M | $0.00 | |
| Stock Based Comp. | $96.2M | $133.1M | $148.2M | $166.6M | $177.9M | $183.0M | $188.4M | $215.9M | $266.1M | $249.3M | $263.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 94.7% | 94.8% | 95.0% | 94.7% | 95.1% | 94.9% | 93.9% | 93.1% | 92.6% | 92.8% | 92.7% | |
| Operating Margin % | 13.1% | -15.8% | 6.9% | 18.6% | -9.9% | 19.6% | 17.4% | 17.7% | 2.4% | 26.1% | 11.6% | |
| Net Margin % | 9.4% | -20.4% | 5.8% | 20.7% | -11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% | 6.7% | |
| EBITDA Margin % | 18.5% | -16.5% | 9.1% | 25.2% | -6.7% | 21.1% | 17.7% | 24.9% | 9.6% | 34.2% | 14.5% | |
| FCF Margin % | 16.7% | -13.3% | 14.0% | 29.3% | -11.7% | 19.0% | 26.3% | 12.6% | 5.9% | 26.3% | 11.4% | |
| ROE % | 24.8% | -19.2% | 5.7% | 17.2% | -11.3% | 25.2% | 7.8% | 11.5% | 0.9% | 24.9% | 7.1% | |
| ROA % | 6.4% | -13.6% | 4.1% | 13.0% | -8.3% | 19.2% | 5.8% | 8.8% | 0.6% | 18.5% | 5.5% | |
| ROIC % | 10.3% | -12.6% | 5.5% | 12.5% | -9.0% | 14.3% | 8.1% | 8.5% | 0.3% | 20.6% | 6.0% | |
| R&D / Revenue % | 52.6% | 86.3% | 63.7% | 53.5% | 83.1% | 48.8% | 46.7% | 44.0% | 61.5% | 39.9% | 57.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.7% | 38.9% | 22.5% | 14.7% | 23.5% | 12.0% | 13.7% | 8.9% | 14.8% | 21.2% | |
| Gross Profit | 44.1% | 39.1% | 22.7% | 14.4% | 24.0% | 11.8% | 12.4% | 7.9% | 14.2% | 21.4% | |
| Operating Income | 186.3% | -267.9% | 153.1% | 211.1% | -165.6% | 322.2% | 1.0% | 10.8% | -84.5% | 1225.6% | |
| Net Income | 1495.8% | -400.5% | 135.0% | 308.2% | -166.2% | 420.8% | -64.1% | 75.4% | -94.5% | 3845.0% | |
| EPS (Diluted) | 1700.0% | -383.3% | 133.3% | 302.0% | -166.3% | 414.0% | -64.4% | 74.3% | -94.3% | 4173.3% | |
| Operating Cash Flow | 252.2% | -130.5% | 461.6% | 111.4% | -117.5% | 701.5% | 29.4% | -48.8% | -32.5% | 321.5% | |
| Free Cash Flow | 204.8% | -210.6% | 228.8% | 140.8% | -149.3% | 282.2% | 56.9% | -48.0% | -46.3% | 443.9% | |
| R&D Expense | 21.3% | 127.9% | -9.7% | -3.7% | 92.0% | -34.2% | 8.8% | 2.6% | 60.2% | -21.4% | |
| SG&A Expense | 54.2% | 20.8% | 18.6% | 7.9% | 10.3% | 43.1% | 35.5% | 15.3% | 5.7% | 12.6% | |
| Total Assets | 62.6% | 40.5% | 14.9% | 29.5% | 3.9% | 38.5% | 18.4% | 16.1% | -19.7% | 27.8% | |
| Book Value / Share | 134.3% | 257.0% | 13.8% | 33.3% | -1.0% | 42.8% | 15.1% | 17.9% | -28.3% | 58.6% | |
| Debt | 5.1% | -96.3% | 50.5% | 66.7% | -21.1% | -5.7% | -7.5% | -7.6% | 13.7% | 59.4% | |
| Diluted Shares | 3.6% | 5.4% | 5.4% | 0.9% | 0.2% | 1.8% | 0.8% | 0.9% | -6.8% | -4.7% |
Valuation
P/E (TTM)56.98
10Y Low / Med / High14.99 / 52.50 / 431.69
P/S4.06
10Y Low / Med / High3.37 / 7.11 / 17.04
P/B4.31
10Y Low / Med / High2.71 / 7.01 / 44.91
EV/EBITDA24.23
10Y Low / Med / High9.23 / 31.02 / 92.08
EV/Revenue3.52
10Y Low / Med / High2.94 / 6.56 / 17.04
P/FCF35.61
10Y Low / Med / High14.23 / 30.26 / 102.11
Intrinsic Value Models (per share)
DCF Value
$113.08
Tangible Book / Share
$26.60
Net Current Assets / Share
$19.02
Graham Number
$35.21
Graham Net-Net
$15.77
Cash / Share
$18.97
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 182.31 | -61.90 | 122.29 | 41.98 | -63.96 | 17.07 | 52.50 | 23.52 | 431.69 | 14.99 | 56.98 | |
| P/S Ratio | 17.04 | 12.61 | 7.18 | 8.69 | 7.11 | 5.42 | 5.25 | 3.80 | 3.37 | 3.75 | 4.06 | |
| P/B Ratio | 44.91 | 11.88 | 7.01 | 7.22 | 7.26 | 4.29 | 4.08 | 2.71 | 4.15 | 3.73 | 4.31 | |
| EV/EBITDA | 92.08 | -73.06 | 72.02 | 31.29 | -98.20 | 22.48 | 24.88 | 11.82 | 31.02 | 9.23 | 24.23 | |
| EV/Revenue | 17.04 | 12.04 | 6.58 | 7.87 | 6.56 | 4.74 | 4.40 | 2.94 | 2.99 | 3.16 | 3.52 |
Analyst Estimates & Quality
Altman Z-Score
10.82
Safe
Piotroski F-Score
6
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $6.04B | $6.28B | $6.61B |
| Net Income | $694.3M | $1.64B | $1.94B |
| EPS | $3.21 | $8.16 | $9.17 |
| # Analysts (EPS) | 14 | 16 | 12 |
Revenue Segments
By Product
| Segment | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| I C L U S I G | $90.0M | $105.0M | $4.7M | $105.8M | $114.3M | $134.1M |
| J A K A F I | $1.91B | $2.22B | $338.0M | $2.74B | $3.21B | $3.55B |
| Milestone And Contract Revenue | $77.5M | $205.0M | $95.0M | $165.0M | $43.0M | $150.0M |
| Olumiant Royalty | $80.4M | $110.9M | $220.9M | $134.5M | $135.6M | $144.6M |
| PEMAZYRE Royalty Revenues | — | $25.9M | $109.4M | $84.7M | $83.9M | $86.7M |
| Tabrecta Royalty Revenues | — | $4.1M | $10.4M | $15.4M | $22.7M | $26.7M |
| M I N J U V I | — | — | $68.5M | $19.7M | $119.2M | $144.6M |
| OPZELURA | — | — | $4.9M | $128.7M | $508.3M | $678.5M |
| ZYNYZ | — | — | — | — | $3.2M | $66.4M |
By Geography
| Segment | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Europe | $90.0M | $105.0M | $124.1M | $147.0M | $260.4M | $323.7M |
| U [S] | — | $2.60B | $2.90B | — | $4.00B | $4.80B |
| UNITED STATES | — | — | — | $3.20B | — | — |